Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06996782 · ClinicalTrials.gov registry record · Phase 1

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
152
Enrollment target
20
Study locations

NCT06996782 is a Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 152 participants, below the 427-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06996782, a Phase 1 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Conditions Studied

Advanced or Metastatic Non-Small-Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Paclitaxel
  • DRUG Rilvegostomig

Study Locations (20)

Other

  • Research Site - Anderlecht
  • Research Site - Hasselt
  • Research Site - Leuven
  • Research Site - Barretos
  • Research Site - Fortaleza
  • Research Site - Natal
  • Research Site - Pelotas
  • Research Site - Porto Alegre
  • Research Site - São Paulo
  • Research Site - São Paulo

Rhode Island

  • Research Site - Providence
  • Research Site - Providence

Arizona

  • Research Site - Phoenix

California

  • Research Site - Santa Rosa

Florida

  • Research Site - Jacksonville

Maryland

  • Research Site - Baltimore

Michigan

  • Research Site - Detroit

Minnesota

  • Research Site - Rochester

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2025-11-24
Est. Completion 2029-02-23
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06996782

The ClinicalTrials.gov registry entry for NCT06996782 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (64% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT06996782 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Rhode Island, Arizona.

Frequently Asked Questions

What is clinical trial NCT06996782 about?

NCT06996782 is a clinical study titled "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

What is the current status of trial NCT06996782?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2025-11-24. Estimated completion is 2029-02-23.

What conditions does trial NCT06996782 study?

This clinical trial studies the following conditions: Advanced or Metastatic Non-Small-Cell Lung Cancer.

What interventions are being tested in trial NCT06996782?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Rilvegostomig (DRUG).

Who is sponsoring clinical trial NCT06996782?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06996782 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Non-Small-Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Non-Small-Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.